Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney J Hicks

Showing results (121-130 of 470) with videos related to

Pageof 47
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2006
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphomaMichael F Leahy, John F Seymour, Rodney J Hicks, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|November 17, 2017
Automated preparation of 2-[<sup>18</sup> F]fluoropropionate labeled peptides using a flexible, multi-stage synthesis platform (iPHASE Flexlab)Mohammad B Haskali, Peter D Roselt, Rodney J Hicks, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2015
Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancerYui Kaneko, William K Murray, Emma Link, et al.
Expert Review of Molecular Diagnostics|December 20, 2007
The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomasKenneth K Khamly, Rodney J Hicks, Grant A McArthur, et al.
Annals of Hematology|January 13, 2016
Short and long-term prognostic implications of a low embolic burden in oncology patients diagnosed with symptomatic pulmonary embolismPierre-Yves Le Roux, Kate Burbury, Michael S Hofman, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|September 23, 2020
The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CTDavid Dudoignon, David A Pattison, Damien Legallois, et al.
Leukemia & Lymphoma|July 28, 2010
The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphomaKieron Dunleavy, George Mikhaeel, Laurie H Sehn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 24, 2020
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on <sup>68</sup>Ga-DOTATATE PET/CT and <sup>18</sup>F-FDG PET/CTLamiaa Zidan, Amir Iravani, Grace Kong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2019
Radiation Dosimetry in <sup>177</sup>Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose FactorsPrice A Jackson, Michael S Hofman, Rodney J Hicks, et al.
Molecular Imaging and Biology|May 25, 2005
The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary originClare L Scott, Iveta Kudaba, Josephine M Stewart, et al.
Pageof 47

Showing results (121-130 of 470) with videos related to

Sort By:
Pageof 47
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2006
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphomaMichael F Leahy, John F Seymour, Rodney J Hicks, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|November 17, 2017
Automated preparation of 2-[<sup>18</sup> F]fluoropropionate labeled peptides using a flexible, multi-stage synthesis platform (iPHASE Flexlab)Mohammad B Haskali, Peter D Roselt, Rodney J Hicks, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2015
Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancerYui Kaneko, William K Murray, Emma Link, et al.
Expert Review of Molecular Diagnostics|December 20, 2007
The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomasKenneth K Khamly, Rodney J Hicks, Grant A McArthur, et al.
Annals of Hematology|January 13, 2016
Short and long-term prognostic implications of a low embolic burden in oncology patients diagnosed with symptomatic pulmonary embolismPierre-Yves Le Roux, Kate Burbury, Michael S Hofman, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|September 23, 2020
The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CTDavid Dudoignon, David A Pattison, Damien Legallois, et al.
Leukemia & Lymphoma|July 28, 2010
The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphomaKieron Dunleavy, George Mikhaeel, Laurie H Sehn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 24, 2020
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on <sup>68</sup>Ga-DOTATATE PET/CT and <sup>18</sup>F-FDG PET/CTLamiaa Zidan, Amir Iravani, Grace Kong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2019
Radiation Dosimetry in <sup>177</sup>Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose FactorsPrice A Jackson, Michael S Hofman, Rodney J Hicks, et al.
Molecular Imaging and Biology|May 25, 2005
The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary originClare L Scott, Iveta Kudaba, Josephine M Stewart, et al.
Pageof 47